- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01175759
Role of Hypersensitivity to Female Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss
Evaluation of the Efficacy and Safety of the EVE- Skin-Test Panel in Detecting Sensitivity to Sex Hormones in Women With Unexplained Recurrent Pregnancy Loss
The EVE- technology is intended for determination of intolerance or sensitivity to female sex hormones among women with hormone-related conditions and for further treatment by desensitization procedure inducing a tolerance to the hormones the women are sensitive to.
This study is designed to evaluate the safety and the ability of the EVE- Skin-Test Panel to detect sensitivity to female sex hormones in subjects with Unexplained Recurrent Pregnancy Loss (URPL) and in Control parous, healthy women.
The Skin Test Panel includes four female hormones and three control solutions.
Hormones from the Skin Test Panel are injected intradermally during the luteal phase of the subject's menstrual cycle. The skin reactions are examined by physician for erythema and wheal after 20 minutes and 48 hours and self-assessed by the patient daily for the following month.
Skin response monthly data is analyzed and compared between unexplained recurrent pregnancy loss (UPRL) and healthy groups.
Following achievement of the significant differences between both groups the immune profile of the healthy and UPRL subjects will be investigated.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: George Füst, Prof.
- Phone Number: 361-212-9351
- Email: fustge@kut.sote.hu
Study Locations
-
-
-
Budapest, Hungary, H1125
- Recruiting
- Depts. Gynecology and Obstetrics and 3rd Dept of Internal Medicine
-
Contact:
- George Füst, Prof.
- Phone Number: 361-212-9351
- Email: fustge@kut.sote.hu
-
Principal Investigator:
- János Rigó, Prof.
-
Principal Investigator:
- Henriette Farkas, Prof.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For both groups:
- Between ages of 20 to 40
- Willing to participate as shown by signing the informed consent form.
For healthy group:
Parous subjects without premenstrual syndrome, as per medical history and subject's report ( PMS questionnaire)
For UPRL:
Women with three or more documented early pregnancy losses.
Exclusion Criteria:
For both groups:
- No hormonal contraceptives (either OC or hormonal IUD (Mirena)), no psychotropic agents (e.g. Antidepressants, anxiolytics, or lithium carbonate) for at least two months prior to screening.
- No hormonal therapy (estrogen or progesterone) for at least two months prior to screening.
- Significant medical or psychiatric disease.
- Severe allergies or an inflammatory illness at the time of enrollment
For healthy group:
- Women who are pregnant or lactating on the day of screening
- Abnormal routine blood tests
For UPRL:
- Hereditary thrombophilias (Factor V Leiden, Activated protein C resistance, MTHFR (C677T), Factor II mutation (G20201A))
One or more abnormal test from the list below:
- Karyotype of either parent (normal: 46XX or 46XY)
- Glucose tolerance test (This can be altered to fasting blood sugar of 100mg/dl or less);
- Toxoplasmosis serology (IgM positive);
- Hysterosalpingogram, 3-D ultrasound or hysteroscopy, thereby excluding anatomical abnormalities, intrauterine adhesions and cervical incompetence;
- Thyroid function (Euthyroid levels;);
- Serum prolactin;
- Normal luteal phase of at least 12 days and plasma progesterone above 24 ng/lL
- Anti nuclear factor (Negative)
- Anticardiolipin antibody by Elisa testing (cut off value <13 GPLu/mL and <7.6 MPLu/mlL) and Lupus anticoagulant (according to Kaolin clotting time (KCT), Russell's viper venom tome (RVVT) or APTT.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Healthy control group
|
Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones:
|
Experimental: UPRL
|
Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators. Hormones:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of subjects with positive wheal responses to the Skin Test Panel in URPL and Control groups
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency and severity of adverse events following a skin test procedure in subjects from URPL and Control groups
Time Frame: 1 month
|
1 month
|
Measurement of cytokine production in subjects from UPRL and Control groups
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: János Rigó, Prof., Gynecology and Obstetrics Dept, Semmelweis University, Budapest, Hungary
- Principal Investigator: Henriette Farkas, Prof., 3rd Dept of Internal Medicine, Semmelweis University, Budapest, Hungary
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 34/2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Abortion, Recurrent
-
Aalborg University HospitalRecruitingInfertility | Recurrent Miscarriage | Recurrent Implantation Failure | Recurrent Pregnancy Loss | Mannose-Binding Lectin Deficiency | Habitual Abortion | Recurrent Spontaneous AbortionDenmark
-
Jianmei XiaCompletedAcupuncture | Coagulation | Ultrasound Therapy | Recurrent Spontaneous AbortionChina
-
Menoufia UniversityCompleted
-
National Nutrition and Food Technology InstituteCompletedRecurrent Abortion
-
Assiut UniversityUnknown
-
Aalborg University HospitalCompletedPregnancy Complications | Recurrent Miscarriage | Pregnancy Loss | Recurrent Pregnancy Loss | Spontaneous Abortion | Mannose-Binding Lectin Deficiency | Habitual AbortionDenmark
-
Genomic Prediction Inc.Active, not recruitingInfertility | Pregnancy Complications | Miscarriage, RecurrentUnited States
-
UMC UtrechtCompleted
Clinical Trials on Skin test panel
-
AllerdermCompletedContact DermatitisDenmark, United States
-
AllerdermCompletedContact DermatitisUnited States, Denmark
-
Mayo ClinicNot yet recruitingSide Effect of Drug | Pharmacogenomic Drug Interaction | Drug Metabolism, Poor, CYP2D6-Related | Ineffective Drug Action | Drug Metabolism, Poor, CYP2C19-RelatedUnited States
-
AltheaDxInnovis LLCCompletedDepression | AnxietyUnited States
-
HippocreatesCompletedAllergy Pollen | Allergy to House DustBelgium
-
AltheaDxCarolina Partners in Mental HealthcareCompletedDepression | AnxietyUnited States
-
Glendale Adventist Medical Center d/b/a Adventist...Caris Life SciencesRecruitingStage III Solid Tumors | Stage IV Solid TumorsUnited States
-
Gynuity Health ProjectsCompleted